Actor portrayals.

Patients trust your knowledge and insights

In fact, nurses received the highest ethics rating—more than any of the other 20 professions rated.1

75% of US adults surveyed said that nurses have “very high” or “high” levels of honesty and ethical standards.1

    Actor portrayal: female nurse looking at her cell phone while sitting outside

    Create Meaningful Connections

    Each shingles experience is personal—that's why understanding risk factors, its impact, and its potential complications is so critical.

    Actor portrayal: male nurse wearing blue scrubs writing on a clipboard

    Care With Confidence

    The decision to vaccinate is important. Learn important facts about SHINGRIX so you feel confident in the discussion.

    Actor portrayal: female nurse speaking with a female patient

    Lead the Conversation

    Discover resources to strengthen your knowledge and to help guide the conversation with your patients.

    DISCUSS SHINGLES

    Shingles could have more of an impact than you realize

    SHINGLES PRESENTS AS A PAINFUL BLISTERING RASH ON ONE SIDE OF THE FACE OR BODY TYPICALLY LASTING 7 TO 10 DAYS AND CAN TAKE 2 TO 4 WEEKS TO HEAL.2

    Nearly everyone ≥50 years of age is at risk for shingles, no matter how healthy they feel.3,4

    1 in 3 people will develop shingles in their lifetime.5

    99.5 percent of people 50 years of age and older are infected with VZV

    Starting at 50 years old, shingles risk sharply increases5

    Increasing age can lead to a natural decline in VZV-specific immunity5

     

    Incidence rate* of herpes zoster by age–United States6

    Incidence rate of herpes zoster by age in the United States bar graph

    SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles) in adults aged 50 years and older.7

    • VZV=varicella zoster virus.

    Patients may experience complications from shingles

    SHINGRIX is not indicated for the prevention of postherpetic neuralgia (PHN) or other herpes zoster-related complications.7

    Patient portrayal: postherpetic neuralgia (PHN) as a complication of shingles

    Postherpetic neuralgia (PHN)

    PHN is a chronic, often debilitating condition that lasts for months (≥90 days) or even years after the shingles rash resolves.8

     

    The risk of PHN increases with age. PHN occurs in 10% to 18% of patients with shingles.8

    Actual patient: herpes zoster ophthalmicus (HZO) as a complication of shingles

    Herpes zoster ophthalmicus (HZO)

    HZO can lead to ocular complications and, in rare cases, vision loss.3

     

    HZO occurs in 10% to 25% of patients with shingles.3

    Shingles could have more of an impact than you realize.

    REVIEW THE COMPLICATIONS
    SHINGRIX delivered greater than 90 percent efficacy against shingles regardless of age in those 50 years and older
    EXPLORE THE CLINICAL DATA
    • †

      Data from the phase 3 ZOE-50 (≥50 years of age) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years old from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.7,9

    WHAT YOU SAY MATTERS

    TO COMMUNICATE THE IMPORTANCE OF VACCINATION WITH SHINGRIX, FOLLOW A SIMPLE 3-STEP PLAN:

    DESCRIBE SHINGLES

    PAINFUL AND DISRUPTIVE

    Shingles is a blistering rash that can be excruciatingly painful, usually lasting 7 to 10 days, and can disrupt everyday activities such as work, family time, and sleep.2,3,10

    LEARN ABOUT SHINGLES

    PERSONALIZE RISK

    AGE AND ADDITIONAL RISK FACTORS

    Starting at age 50, the risk of shingles sharply increases.5 In addition to age, certain chronic conditions as well as psychological stress have been associated with an increased risk of shingles.11

    SEE THE RISK FACTORS

    RECOMMEND SHINGRIX

    PROVEN OUTSTANDING EFFICACY

    SHINGRIX, administered as a 2-dose series, was proven more than 90% effective in preventing shingles in people 50 years and older.7,‡

    The most common side effects are pain, redness, and swelling at the injection site, muscle pain, tiredness, headache, shivering, fever, and upset stomach.7

    EXPLORE THE DATA
    • ‡

      Data from the phase 3 ZOE-50 (≥50 years old) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years old from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.7,9

    RESOURCES

    The best conversation starts with the right information

    THE FOLLOWING RESOURCES CAN BE USED TO HELP TURN EACH PATIENT CONVERSATION INTO A PREVENTION OPPORTUNITY

    What to Expect Pamphlet

    Book Appointments at ScheduleSHINGRIX.com

    Visit the Resources page for more

    Indication & Important Safety Info

    Indication

    Important Safety Information

    Indication

    SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

    • in adults aged 50 years and older.
    • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

    SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

    Important Safety Information

    • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
    • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
    • In postmarketing observational studies, an increased risk of Guillain-Barré syndrome has been observed during the 42 days following vaccination with SHINGRIX
    • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
    • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
    • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)  
    • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)  
    • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
    • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
    • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
    • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

     

    Please see full Prescribing Information.

    To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or
    1-888-825-5249, or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

    References

    1. Brenan M. Nurses continue to lead in honesty and ethics ratings. Gallup. January 12, 2026. Accessed January 14, 2026. https://news.gallup.com/poll/700736/nurses-continue-lead-honesty-ethics-ratings.aspx

    2. Shingles symptoms and complications. Centers for Disease Control and Prevention. Reviewed April 19, 2024. Accessed March 26, 2025. https://www.cdc.gov/shingles/signs-symptoms/index.html

    3. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1-30.

    4. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(supp| 1):S111-S118.

    5. Clinical overview of shingles (herpes zoster). Centers for Disease Control and Prevention. Reviewed June 27, 2024. Accessed December 4, 2025. https://www.cdc.gov/shingles/hcp/clinical-overview/index.html

    6. Shingles facts and stats. Centers for Disease Control and Prevention. Reviewed April 12, 2024. Accessed January 14, 2026. https://www.cdc.gov/shingles/data-research/index.html

    7. Prescribing Information for SHINGRIX.

    8. Clinical features of shingles (herpes zoster). Centers for Disease Control and Prevention. Reviewed May 10, 2024. Accessed September 7, 2025. https://www.cdc.gov/shingles/hcp/clinical-signs/index.html

    9. Data on file. Study 113077 (NCT01165229). GSK Study Register. Study entry at: https://www.gsk-studyregister.com/en/trial-details/?id=113077

    10. Curran D, Matthews S, Boutry C, Lecrenier N, Cunningham AL, Schmader K. Natural history of herpes zoster in the placebo groups of three randomized phase III clinical trials. Infect Dis Ther. 2022;11(6):2265-2277.

    11. Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):1-8.

      Questions About SHINGRIX?

      Call: 1-800-772-9292

      Available Monday - Friday

      8:30 am to 5:30 pm ET